Gritstone Oncology

gritstoneoncology.com

Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

IMMAGENE AND SELVITA ANNOUNCE INTEGRATED DRUG DISCOVERY COOPERATION

Selvita | February 07, 2022

news image

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Read More

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More

Industry Outlook

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

news image

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More

AZELASTINE, AN ANTIHISTAMINE NASAL SPRAY IDENTIFIED AS A PREVENTIVE OR POST-EXPOSURE ANTI-COVID-19 APPROACH

CEBINA | July 13, 2020

news image

CEBINA GmbH, an Austrian biotech company, announces positive results of its COVID-19 drug repurposing project with the identification of commonly used approved drugs with activity against SARS-CoV-2 infection in in vitro assays. One of these drugs, Azelastine an antihistamine currently available as a nasal spray, has been identified as a potential topical preventive or post-exposure anti-COVID-19 approach.CEBINA, in collaboration with Professor Robert Konrat, a renowned structural biologis...

Read More
news image

Research

IMMAGENE AND SELVITA ANNOUNCE INTEGRATED DRUG DISCOVERY COOPERATION

Selvita | February 07, 2022

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Read More
news image

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More
news image

Industry Outlook

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More
news image

AZELASTINE, AN ANTIHISTAMINE NASAL SPRAY IDENTIFIED AS A PREVENTIVE OR POST-EXPOSURE ANTI-COVID-19 APPROACH

CEBINA | July 13, 2020

CEBINA GmbH, an Austrian biotech company, announces positive results of its COVID-19 drug repurposing project with the identification of commonly used approved drugs with activity against SARS-CoV-2 infection in in vitro assays. One of these drugs, Azelastine an antihistamine currently available as a nasal spray, has been identified as a potential topical preventive or post-exposure anti-COVID-19 approach.CEBINA, in collaboration with Professor Robert Konrat, a renowned structural biologis...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us